久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

World-first drug to be launched in China

By Liu Zhihua | chinadaily.com.cn | Updated: 2018-12-19 13:36
Share
Share - WeChat
A worker leaves the AstraZeneca research facility in Loughborough, the United Kingdom. [Photo/Agencies]

AstraZeneca China announced on Tuesday that new anemia drug roxadustat has received approval from the National Medical Products Administration.

The drug was developed in collaboration with FibroGen China.

China has become the first country worldwide to approve the oral anemia treatment hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI).

AstraZeneca said the drug was expected to be launched in China during the second half of 2019.

Roxadustat, Chinese brand name Ai Rui Zhuo(愛瑞卓), has achieved three primary breakthroughs: it's the first drug to the adopt the HIF mechanism; the first of its kind developed and incubated in China, and the first approved in China before any other market globally, the company said.

FibroGen China was responsible for the clinical trials and registration of roxadustat in China, and now holds the certificate of drug registration issued by the NMPA.

Following the approval, FibroGen China will manage manufacturing, medical affairs and distribution.

AstraZeneca will manage its launch and commercialization.

According to the NMPA approval, roxadustat is to be used in the treatment of anemia caused by chronic kidney disease (CKD) in patients who are dialysis-dependent (DD).The medicine can be prescribed to patients who use hemodialysis or peritoneal dialysis.

There are over 120 million CKD patients in China, and anemia is one of the complications of CKD, occurring at a rate of up to 98.2 percent in patients on dialysis, according to medical journals Lancet and Chinese Journal of Nephrology.

If anemia is not controlled, it increases cardiovascular risks, as well as mortality in patients on dialysis, and may affect patients' mental health and social functions, imposing a heavy burden on patients, their families and society.

According to clinical data in China, roxadustat can effectively increase and keep hemoglobin in dialysis patients with anemia caused by CKD, AstraZeneca said.

The development of roxadustat ends a long period in which there were no new drugs developed by a new mechanism for the treatment of CKD-caused anemia, said Chen Xiangmei, member of the Chinese Academy of Engineering and head of the PLA Institute of Kidney Diseases.

AstraZeneca also attributed the fast approval to the Chinese government's efforts in supporting pharmaceutical innovation and providing more quality new drugs to Chinese patients.

Leon Wang, executive vice president, international and China President at AstraZeneca, said: "Roxadustat's approval in China demonstrated the determination of the Chinese government in accelerating the supply of urgently needed new drugs to Chinese patients and supporting pharmaceutical innovation.

"In the future, AstraZeneca will work closely with the government to increase the accessibility of roxadustat in China and benefit more Chinese patients.

"At the same time, in response to the Chinese government's call for pharmaceutical innovation, we will build the local incubation platform to make more novel drugs benefiting Chinese patients first and open up China's pharmaceutical innovations to the world."

Chen Nan, a professor with Shanghai Jiao Tong University School of Medicine, who led principal investigator in the phase-three clinical trial of roxadustat in China, said: "Thanks to the improvement of China's pharmaceutical innovation atmosphere, Chinese researchers now have much better chance to show their excellence together with international peers, to further the global clinical development of first-in-class innovative drugs and to succeed in incubating them in China first.

"Our work is taking the lead not only in terms of speed, but also meets international standards in terms of quality, which demonstrates the research and development strength of China's healthcare professionals."

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 韩国一级片视频 | 国产成人亚洲精品无广告 | 成人免费观看网欧美片 | 我要看欧美精品一级毛片 | 成年女人免费毛片视频永久 | 国产精品成aⅴ人片在线观看 | 武松大战潘金莲三级在线 | 成人男女网18免费看 | 妖精www成人动漫在线观看 | 免费精品在线 | 欧美日韩国产免费一区二区三区 | 91日韩精品天海翼在线观看 | 白云精品视频国产专区 | 亚洲综合网在线观看首页 | 亚洲精品国产一区二区三 | 男女视频免费观看 | 一本色道久久88亚洲综合 | 久爱综合 | 91精品国产爱久久久久 | 精品日韩在线视频一区二区三区 | 久久99精品久久久久久 | 97国产影院 | 精品国产自在在线在线观看 | 一级色黄| 日本www免费视频网站在线观看 | 亚洲一级网站 | 古代级a毛片可以免费看 | 中国一级做a爰片久久毛片 中日韩欧美一级毛片 | 国产精品久久久久久久久久日本 | 美女张开腿让男人 | 亚洲香蕉一区二区三区在线观看 | 99精品免费在线观看 | 国产成人精品免费视频大 | 中文字幕在线观看一区二区三区 | 免费a级黄毛片 | 日韩一级伦理片 | 久久91视频 | 国产自愉自愉全免费高清 | 亚洲成av人片在线观看 | 日韩一级片在线观看 | 亚洲国产成人久久综合野外 |